Bank of America Spends $250M Annually on Weight Loss Drugs

Bank of America is allocating an annual budget of $250 million or more to provide weight loss drugs, specifically GLP-1 agonists, to its employees. This significant expenditure is part of a broader $2 billion annual wellness package dedicated to employee healthcare at the financial institution, which has an estimated $436 billion in assets. CEO Brian Moynihan articulated the bank's rationale in a CNBC interview, stating, “What we see is a great impact on the employees,” emphasizing the company's long-standing commitment to both mental and physical wellness. While employees may be responsible for premiums or copays, Bank of America covers the substantial remainder of the drug costs.

Moynihan highlighted the perceived benefits of this investment, noting that it contributes to a healthier workforce by potentially lowering the incidence of certain health issues, such as heart problems, even for individuals who may not exhibit all pre-existing risk factors. He acknowledged that some long-term health advantages might not be fully realized by the company, as employees might experience benefits years after their tenure with Bank of America has concluded. Despite this, Moynihan affirmed the investment as ethically sound and aligned with the bank's objective to be a "great place to work." The bank monitors employee progress on these medications, offering coaching and support to facilitate weight loss and overall well-being. Bank of America declined to provide further comment to Fortune regarding this initiative.

The increasing popularity of weight loss drugs like Ozempic, Wegovy, and Zepbound has positioned them as a desirable employee benefit. Recent data indicates that nearly one-third of workers would consider switching jobs to secure coverage for GLP-1 medications. This trend underscores a broader shift in corporate benefits, where employers are increasingly recognizing the value of supporting employee health through pharmaceutical interventions. However, the provision of these drugs varies significantly across industries and companies. Reports suggest that only 60% of firms currently offer weight loss drugs, and often, their coverage is primarily restricted to patients with type 2 diabetes, the original intended use for GLP-1 agonists. Bank of America's comprehensive approach, extending coverage beyond specific medical conditions to a broader employee wellness program, represents a notable departure from this more limited industry standard.